Protein kinase deficient, immunologically active CMVpp65 mutants
This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and protein vaccines. Therefore, the invention provides proteins and DNAS, as well as vaccines comprising the proteins and DNAs, including cellular vaccines and vectors. Other embodiments of the invention relate to methods of enhancing immune response and vaccinating against CMV, including gene therapy methods and vectors.
1. A vaccine composition which comprises a mutant cytomegalovirus pp65 protein that lacks protein kinase activity and that when administered to a mammal elicits a CTL immune response against cells infected with cytomegalovirus, wherein said cytomegalovirus pp65 protein contains a site-specific mutation at amino acid 436 or at both amino acid 436 and amino acid 465.
2. A vaccine composition of claim 1 wherein said cytomegalovirus pp65 protein contains the K436N mutation.
3. A vaccine composition of claim 1 which further comprises an adjuvant.
4. A method of enhancing immunity to cytomegalovirus which comprises administering a vaccine composition of claim 1 .
5. A vaccine composition which comprises a mammalian expression vector which contains a nucleic acid that encodes a mutant cytomegalovirus pp65 protein that lacks protein kinase activity and that when administered to a mammal elicits a CTL immune response against cells infected with cytomegalovirus, wherein said cytomegalovirus pp65 protein contains a site-specific mutation at amino acid 436 or at both amino acid 436 and amino acid 465.
6. A vaccine composition of claim 5 wherein said pp65 protein contains the K436N mutation.
7. A vaccine composition of claim 5 wherein said nucleic acid encodes CMV pp65mll.